2Levine RJ,Lam C,Qian C. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia[J].New England Journal of Medicine,2006,(11):992-1005.
3Thomas FM,Kee HL,Emmanuelle Pare. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy[J].AGOG,2012,(05):407-411.
4Venkatesha S,Toporsian M,Lam C. Soluble endoglin contributes to the pathogenesis of preeclampsia[J].Nature Medicine,2006,(03):642-649.
5Olsson AK,Dimberg A,Kreuger J. VEGF receptor signalling-in control of vascular function[J].Nature Reviews Molecular Cell Biology,2006,(04):359-371.
6Kupferminc M J,Daniel Y,Englender T. Vascular endothelial growth factor is increased in patients with preeclampsia[J].American Journal of Reproductive Immunology,1997,(04):302-306.
7Malou PHS,Emily MH,Victor May. The adaptation of the blood-brain barrier to vascular endothelial growth factor and placental growth factor during pregnancy[J].FASEB,2012,(01):355-362.
8Lee WH,Cho H J,Sonntag WE. Radiation attenuates physiological angiogenesis by differential expression of VEGF,Ang-1,Tie-2 and Ang-2 in rat brain[J].Radiation Research,2011,(06):753-760.
9Ebos JM,Lee CR,Bogdanovic E. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth[J].Cancer Research,2008,(15):521-529.
10Albuquerque RJ,Hayashi T,Cho WG. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth[J].Nature Medicine,2009,(05):1023-1030.
